Compound class:
Synthetic organic
Comment: The chemical structure for glovadalen was obtained from proposed INN list 130 (Feb. 2024), in which the compound is described as a dopamine D1 receptor positive allosteric modulator (PAM). It is claimed in UCB Biopharma's patent WO2021001288A1 [1]. Exploration of UCB's declared pipeline suggests that glovadalen may be their clinical lead UCB0022, that is being developed for Parkinson's disease [2]. We will update this entry when the structure for UCB0022 and/or glovadalen is published.
|
|
Bioactivity Comments |
Preclinical data that was presented at the 2022 International Congress of the International Parkinson and Movement Disorder Society, indicates that UCB0022 enhances the potency of dopamine at D1 receptors by 10-fold (Abstract 1074; Preclinical characterization of UCB0022, an oral, brain penetrant, selective, clinical-stage positive allosteric modulator of the dopamine 1 receptor (D1 PAM)). |